ANTIBIOTIC SUSCEPTIBILITY PATTERN AND ESBL PREVALENCE IN ESCHERICHIA COLI ISOLATES FROM PUS SAMPLES IN A TERTIARY CARE HOSPITAL
Keywords:
ESBL (Extended spectrum beta lactamase), Escherichia coli, Ceftazidime and Ceftaclav (Ceftazidime clavulanic acid)Abstract
Objective: Escherichia coli is one of the most common etiological agent isolated from various infections. ESBL (Extended spectrum beta lactamase) producing strains of Escherichia coli have become a great therapeutic challenge to the clinicians in managing such infections. The aim and objective of the present study is to find out the antibiotic susceptibility pattern and to assess the prevalence of ESBL producers among the Escherichia coli isolates.
Methods: 100 isolates of Escherichia coli from pus samples identified by standard conventional methods were included in the study. Antibiotic sensitivity testing was carried out using the Kirby Bauer's disc diffusion method. Isolates showing resistance to third generation cephalosporins were subjected to phenotypic confirmatory test to confirm ESBL production.
Results: The antibiogram revealed higher susceptibility percentage to Amikacin, Gentamicin and Levofloxacin. Higher resistance rate was noted for Amoxyclav, Ciprofloxacin, Cefotaxime, Ceftazidime and Ertapenem. All the isolates were found to be susceptible to Imipenem and Tigecycline. 36% of the Escherichia coli isolate were detected to be ESBL producers.
Conclusion: ESBL producing strains of Escherichia coli will cause therapeutic failure and also contribute to multidrug resistance. Hence routine surveillance for ESBL production and infection control methods should be made mandatory.
Downloads
References
Bhattacharya S. ESBL–from petri dish to the patient. Indian J Med Microbiol 2006:24:20–4.
Chaudhary U, Aggarwal R. ESBL-An emerging threat to clinical therapeutics. Indian J Med Microbiol 2004:22(2):75-80.
Sameena K, Lakshmi K, Chitralekha S, And Aishwarya Jr. Detection of extended spectrum beta lactamasesin Escherichia coli isolates. Int J Pharm Biol Sci 2013:4(2): B1201–4.
Iroha IR, ES Amadi, JO Orji, AC Ogabus, AE Oji, CO Esimone. The interaction between gentamicin and fluoroquinolones against ESBL producing clinical isolates of Escherichia coli. Trends Med Res 2008:3:90–4.
Quinteros M, Radice M, Gardella N, Rodriguez MM, Costa N, Korbenfeld D. Extended spectrum beta lactamases in Enterobacteriaceae in Buenos Aires, Argentina, Public Hospitals. Antimicrob Agents Chemother 2003:47:2864-7.
Akata F, Tatman-Otkum M, Ozkan E, Tansel O, Otkum M, Tugrul M. Prevalence of extended spectrum beta lactamases produced by nosocomial isolates of enterobacteriaceae in Trakta University Hospital, Turkey. New Microbiol 2003:26:257-62.
Hansotia JB, Agrawal V, Pathak AA, Saoji AM. Extended spectrum beta lactamases mediated resistance to third generation cephalosporins in Klebsiella pneumonia in Nagpur, Central India. Indian J Med Res 1997:105:156-61.
Bradford PA. Extended-spectrum betalactamases in the 21st century: Characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001:14:933-51.
Paterson DL, Bonomo RA. Extendedspectrum ß-lactamases: a clinical update. Clin Microbiol Rev 2005:18:657-86.
R Eshwar Singh, KG Raghukumar, M Veena, G Vishwanath, PN Sridhar Rao, BV Murlimanju. ESBL production: resistance pattern in escherichia coli and klebsiellapneumoniae, A Study by NCCLS method. RJPBCS 2012:3(1):559–65.
Yazdi M, Nazemi A, Mirinargasi M, Jafarpour M, Sharifi SH. Genotypic versus Phenotypic methods to detect Extended-Spectrum Beta-Lactamases [ESBLs] in Uropathogenic Escherichia coli. Ann Biol Res 2012:3(5):2454-8.
Gupta V, Yadav A, Joshi RM. Antibiotic resistance pattern in uropathogen. Indian J Med Microbiol 2002:20:96-8.
Gales AC, Sader HS, Jones RN. Sentry participants group [Latin America]. Urinary tract infections trends in the American hospitals: reports from the Sentry Antimicrobial Surviellance programme. Diagn Microbial Infect Dis 2002:44:289-99.
Iqbal M, Patel IK, Shal SH, Ain Q, Barrey N, Kiani Q. Susceptibility patterns of Escherichia coli prevalence of multidrug resistant isolates and extended spectrum beta lactamase phenotype. J Pak Med Assoc 2002:52:407-11.